STUDY OBJECTIVE:

 

To investigate the pharmacodynamic and pharmacokinetic profiles of fluticasone furoate (FF)/vilanterol (VI) - a fixed-dose combination of an inhaled corticosteroid (ICS) and a long-acting β2 -agonist for the treatment of asthma and chronic obstructive pulmonary disease - after single and repeat administration in healthy Chinese subjects.

 

DESIGN:

 

Double-blind, placebo-controlled, single-site, randomized, four-way crossover study.

 

SETTING:

 

The Clinical Pharmacological Research Centre at Peking Union Medical College Hospital [PUMCH]) in Beijing, China.

 

SUBJECTS:

 

Sixteen healthy, nonsmoking Chinese adults.

 

(후략)